Precigen (NASDAQ:PGEN) Releases Earnings Results, Beats Estimates By $0.01 EPS

Precigen (NASDAQ:PGEN) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01, FiscalAI reports. Precigen had a positive return on equity of 2,317.96% and a negative net margin of 2,588.21%.The company had revenue of $23.25 million during the quarter, compared to analysts’ expectations of $20.81 million.

Here are the key takeaways from Precigen’s conference call:

• PAPZIMEOS delivered a strong first full quarter of sales, with Q1 2026 net product revenue of $21.6 million versus $3.4 million in Q4 2025, and management said momentum is continuing into Q2.
• The company said launch adoption is broadening across major medical centers and community practices, with about 400 patients registered in the hub and roughly 25% coming from community settings.
• Precigen highlighted strong access dynamics, citing more than 90% of insured lives covered in the U.S. and the recent permanent J-code as factors that should simplify claims and support broader uptake.
• Financially, the quarter was better than the company’s prior launch phase, with operating loss of just $6 million and cash, cash equivalents and investments of $56.7 million; management reiterated it expects to reach cash flow break-even by the end of 2026 without needing to access capital markets.
• Beyond the commercial launch, Precigen said it plans to start a pediatric PAPZIMEOS trial in Q4 2026, expects EMA review to continue, and will provide ASCO durability data next month along with additional PRGN-2009 updates later this year.

Precigen Price Performance

PGEN traded up $0.07 during trading on Wednesday, reaching $4.15. The stock had a trading volume of 2,744,939 shares, compared to its average volume of 4,198,495. The stock has a market cap of $1.48 billion, a PE ratio of -3.10 and a beta of 1.07. The company has a debt-to-equity ratio of 4.46, a quick ratio of 2.83 and a current ratio of 3.09. Precigen has a one year low of $1.26 and a one year high of $5.47. The business has a 50-day moving average of $3.80 and a 200-day moving average of $4.07.

Insider Buying and Selling at Precigen

In other news, Director Randal J. Kirk sold 4,772,781 shares of the business’s stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $3.30, for a total value of $15,750,177.30. Following the completion of the sale, the director directly owned 302,213 shares in the company, valued at approximately $997,302.90. The trade was a 94.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 47.10% of the company’s stock.

Institutional Trading of Precigen

A number of institutional investors have recently modified their holdings of the company. AQR Capital Management LLC raised its holdings in Precigen by 216.9% in the 1st quarter. AQR Capital Management LLC now owns 63,179 shares of the biotechnology company’s stock worth $94,000 after purchasing an additional 43,245 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Precigen by 12.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 81,610 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 9,043 shares in the last quarter. Strs Ohio bought a new position in Precigen in the 1st quarter worth $70,000. Geode Capital Management LLC raised its holdings in Precigen by 7.7% in the 2nd quarter. Geode Capital Management LLC now owns 3,749,182 shares of the biotechnology company’s stock worth $5,325,000 after purchasing an additional 269,580 shares in the last quarter. Finally, Creative Planning raised its holdings in Precigen by 127.8% in the 2nd quarter. Creative Planning now owns 94,291 shares of the biotechnology company’s stock worth $134,000 after purchasing an additional 52,901 shares in the last quarter. 33.51% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. HC Wainwright boosted their price objective on shares of Precigen from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Wall Street Zen upgraded shares of Precigen from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Zacks Research raised Precigen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Citizens Jmp lifted their price target on Precigen from $8.00 to $9.00 and gave the company a “market outperform” rating in a research note on Thursday, March 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a report on Tuesday, April 21st. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Precigen currently has a consensus rating of “Hold” and an average target price of $9.50.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.